Learning Center
Targeting FcRn in generalized myasthenia gravis with RYSTIGGO® (rozanolixizumab-noli)
Includes a Live Web Event on 02/18/2026 at 1:00 PM (EST)
This session will discuss RYSTIGGO® (rozanolixizumab-noli), a subcutaneous infusion that blocks neonatal Fc receptor (FcRn), in the management of adults with anti-acetylcholine receptor (anti-AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive (Ab+) generalized myasthenia gravis (gMG). Within the evolving gMG treatment landscape, understanding its clinical application is key to supporting shared decision-making that aligns with patients’ unique needs and preferences. Learners will explore best practices for RYSTIGGO administration and review recent data from the Phase 3 MycarinG and extension studies. In this session, we will apply clinical insights to a patient case and explore practical strategies for incorporating RYSTIGGO into treatment plans for adults with anti-AChR or anti-MuSK Ab+ gMG.
Learning Objectives: At the conclusion of this session, learners will be able to:
- Apply best practices for the administration of RYSTIGGO
- Analyze and interpret recent clinical trial data for RYSTIGGO in adults with anti-AChR or anti-MuSK Ab+ gMG
- Personalize treatment strategies and goals using a patient case with gMG to foster critical thinking
Deena Rodney, MSN, APRN, ATC, AQH
Deena M. Rodney, MSN, APRN, ATC, AQH, started her nursing career as a bedside neurology and psychiatric nurse. Shortly into her career, she transitioned to a unit educator for the neuroscience department (neurology medicine, surgical, and intensive care unit [ICU]). She found her strength in educating and grew into an administrator position developing graduate nurse programs for specialty units and training preceptors. Ms Rodney also held her roots to neurology, and post-graduate, accepted her current position of 16 years as community neurology APRN, caring for general neurology patients and rounding at one of the largest hospitals in central Florida. As she honed her profession, she developed a strength in care for the neuromuscular patient. In her practice, Ms Rodney is able to manage all aspects of patient care, including involvement in research and monitoring patients in the infusion suite. She has a mutual passion to care for the whole person and to educate providers.
CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.
Contact Hours: This session has been approved for 1 contact hour
Expiration date for receipt of contact hours: February 18, 2029
To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.
The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.
-
Register
- Non-member - Free!
- Member - Free!
Key:
Complete
Next
Failed
Available
Locked